Which has preferable earnings & valuation, OCS or OTLK?

Oncobiologics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 517.02 -$119.44M -$2.13 N/A Oncobiologics $1.35M 190.42 -$62.42M -$1.17 N/A

Is OCS or OTLK more profitable?

Oncobiologics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oncobiologics' return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Oncobiologics N/A N/A -291.28%

Oncobiologics (OTLK) Competitors

$1.73 +0.18 (+11.61%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 0.00 (-0.29%)

As of 07:59 PM Eastern

Compare

OTLK vs. SPRY, ZVRA, OCS, GYRE, and ESPR

Should you buy Oncobiologics stock or one of its competitors? MarketBeat compares Oncobiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncobiologics include ARS Pharmaceuticals (SPRY), Zevra Therapeutics (ZVRA), Oculis (OCS), Gyre Therapeutics (GYRE), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.

How does Oncobiologics compare to ARS Pharmaceuticals?

Oncobiologics (NASDAQ:OTLK) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Oncobiologics currently has a consensus target price of $6.50, indicating a potential upside of 275.72%. ARS Pharmaceuticals has a consensus target price of $28.20, indicating a potential upside of 270.57%. Given Oncobiologics' higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Oncobiologics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oncobiologics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Oncobiologics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Oncobiologics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.26 beat ARS Pharmaceuticals' score of 0.57 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Overall Sentiment
Oncobiologics	Positive
ARS Pharmaceuticals	Positive

Oncobiologics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A
ARS Pharmaceuticals	$84.28M	8.97	-$171.30M	-$2.01	N/A

Summary

Oncobiologics and ARS Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Zevra Therapeutics has a net margin of 101.58% compared to Oncobiologics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Oncobiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Oncobiologics	N/A	N/A	-291.28%

In the previous week, Zevra Therapeutics had 2 more articles in the media than Oncobiologics. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.26 beat Zevra Therapeutics' score of 0.89 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Positive
Oncobiologics	Positive

Zevra Therapeutics has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.25	$83.23M	$1.99	6.56
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zevra Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Zevra Therapeutics currently has a consensus target price of $29.29, suggesting a potential upside of 124.24%. Oncobiologics has a consensus target price of $6.50, suggesting a potential upside of 275.72%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Zevra Therapeutics beats Oncobiologics on 13 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Oculis?

Oculis (NASDAQ:OCS) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Oculis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

In the previous week, Oculis had 2 more articles in the media than Oncobiologics. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.26 beat Oculis' score of 0.78 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oculis	Positive
Oncobiologics	Positive

Oncobiologics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oncobiologics' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Oncobiologics	N/A	N/A	-291.28%

22.3% of Oculis shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oncobiologics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	517.02	-$119.44M	-$2.13	N/A
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A

Oculis presently has a consensus target price of $38.33, suggesting a potential upside of 196.47%. Oncobiologics has a consensus target price of $6.50, suggesting a potential upside of 275.72%. Given Oncobiologics' higher probable upside, analysts clearly believe Oncobiologics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oncobiologics beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Gyre Therapeutics?

Oncobiologics (NASDAQ:OTLK) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oncobiologics and Oncobiologics both had 2 articles in the media. Gyre Therapeutics' average media sentiment score of 1.94 beat Oncobiologics' score of 1.26 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncobiologics	Positive
Gyre Therapeutics	Very Positive

Oncobiologics currently has a consensus target price of $6.50, indicating a potential upside of 275.72%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 168.14%. Given Oncobiologics' higher possible upside, equities research analysts clearly believe Oncobiologics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Oncobiologics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Oncobiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Gyre Therapeutics has higher revenue and earnings than Oncobiologics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A
Gyre Therapeutics	$116.59M	6.06	$5.03M	-$0.09	N/A

Oncobiologics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

Summary

Gyre Therapeutics beats Oncobiologics on 11 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Esperion Therapeutics has higher revenue and earnings than Oncobiologics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Esperion Therapeutics presently has a consensus price target of $5.54, indicating a potential upside of 74.21%. Oncobiologics has a consensus price target of $6.50, indicating a potential upside of 275.72%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Esperion Therapeutics had 4 more articles in the media than Oncobiologics. MarketBeat recorded 6 mentions for Esperion Therapeutics and 2 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.26 beat Esperion Therapeutics' score of 1.22 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Esperion Therapeutics	Positive
Oncobiologics	Positive

Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Oncobiologics' net margin of 0.00%. Oncobiologics' return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Oncobiologics	N/A	N/A	-291.28%

Summary

Esperion Therapeutics beats Oncobiologics on 8 of the 14 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$230.31M	$3.68B	$6.85B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	-1.48	20.98	27.04	24.38
Price / Sales	190.42	311.16	524.25	93.48
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	-2.88	8.54	10.80	6.33
Net Income	-$62.42M	$23.83M	$3.59B	$331.02M
7 Day Performance	18.49%	-3.53%	-2.24%	-1.09%
1 Month Performance	41.80%	6.29%	3.12%	-0.49%
1 Year Performance	-25.43%	48.64%	26.30%	19.90%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	3.7302 of 5 stars	$1.73 +11.6%	$6.50 +275.7%	-25.1%	$230.31M	$1.35M	N/A	20	Positive News
SPRY ARS Pharmaceuticals	3.2642 of 5 stars	$8.33 -2.7%	$28.20 +238.5%	-56.2%	$850.04M	$84.28M	N/A	90
ZVRA Zevra Therapeutics	4.3641 of 5 stars	$13.97 -0.1%	$29.29 +109.6%	+5.2%	$826.43M	$106.47M	11.01	20	Analyst Upgrade
OCS Oculis	3.022 of 5 stars	$13.80 -2.3%	$38.33 +177.8%	-27.2%	$818.74M	$1.45M	N/A	2	Positive News Analyst Downgrade
GYRE Gyre Therapeutics	2.5165 of 5 stars	$7.26 -1.1%	$17.00 +134.2%	-15.4%	$818.33M	$116.59M	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. SPRY, ZVRA, OCS, GYRE, and ESPR

How does Oncobiologics compare to ARS Pharmaceuticals?

Summary

How does Oncobiologics compare to Zevra Therapeutics?

Summary

How does Oncobiologics compare to Oculis?

Summary

How does Oncobiologics compare to Gyre Therapeutics?

Summary

How does Oncobiologics compare to Esperion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. SPRY, ZVRA, OCS, GYRE, and ESPR

How does Oncobiologics compare to ARS Pharmaceuticals?

Do analysts rate OTLK or SPRY?

Which has more risk and volatility, OTLK or SPRY?

Do insiders and institutionals have more ownership in OTLK or SPRY?

Is OTLK or SPRY more profitable?

Does the media prefer OTLK or SPRY?

Which has preferable valuation & earnings, OTLK or SPRY?

Summary

How does Oncobiologics compare to Zevra Therapeutics?

Is ZVRA or OTLK more profitable?

Does the media prefer ZVRA or OTLK?

Which has better valuation and earnings, ZVRA or OTLK?

Do institutionals & insiders have more ownership in ZVRA or OTLK?

Which has more volatility and risk, ZVRA or OTLK?

Do analysts rate ZVRA or OTLK?

Summary

How does Oncobiologics compare to Oculis?

Which has more risk & volatility, OCS or OTLK?

Does the media refer more to OCS or OTLK?

Is OCS or OTLK more profitable?

Do institutionals and insiders hold more shares of OCS or OTLK?

Which has preferable earnings & valuation, OCS or OTLK?

Do analysts recommend OCS or OTLK?

Summary

How does Oncobiologics compare to Gyre Therapeutics?

Do institutionals & insiders believe in OTLK or GYRE?

Does the media favor OTLK or GYRE?

Do analysts rate OTLK or GYRE?

Is OTLK or GYRE more profitable?

Which has better valuation and earnings, OTLK or GYRE?

Which has more risk & volatility, OTLK or GYRE?

Summary

How does Oncobiologics compare to Esperion Therapeutics?

Which has better earnings & valuation, ESPR or OTLK?

Do institutionals and insiders believe in ESPR or OTLK?

Do analysts recommend ESPR or OTLK?

Does the media refer more to ESPR or OTLK?

Which has more volatility & risk, ESPR or OTLK?

Is ESPR or OTLK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools